| SHADD | Target | Product | Disease | Project | Discovery | Development | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Strategy | Hit | Lead | L/O | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Launched | |||||
| Pharmacophore Analysis |
STAT3/NFkB | selective STAT3 allosteric inhibitor |
Lupus/IBD Osteoporosis/ |
HCB-SF501 | |||||||||
| Unknown | STAT1/3 Inducer |
Hair growth | HCB-SF101 | ||||||||||
| Asymmetric Synthesis |
New Drug NLRP3… |
Biological Testing ~ PI Drugs First-in-class |
HCB-AF101 | ||||||||||
| Chiral Reagent /API |
Unnatural Amino Acid, ester/API | ||||||||||||
| Selective Cancer |
EGFR/ BTK Mutation(?) |
EGFR/ BTK | Cancer (MDA-MB-468) |
HCB-CF101 | |||||||||
| Warhead/Hybrid approach |
Protac/ADC/ Linker / Hybrid | Alzheimer’s / Cancer |
HCB-WH101 | ||||||||||